Validity of composite end points in clinical trials

Victor M. Montori, Gaietà Permanyer-Miralda, Ignacio Ferreira-González, Jason W. Busse, Valeria Pacheco-Huergo, Dianne Bryant, Jordi Alonso, Elie A. Akl, Antònia Domingo-Salvany, Edward Mills, Ping Wu, Holger J. Schünemann, Roman Jaeschke, Gordon H. Guyatt

Research output: Contribution to journalReview article

269 Scopus citations

Abstract

Use of composite end points as the main outcome in randomised trials can hide wide differences in the individual measures. How should you apply the results to clinical practice?

Original languageEnglish (US)
Pages (from-to)594-596
Number of pages3
JournalBritish medical journal
Volume330
Issue number7491
StatePublished - Mar 12 2005

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Montori, V. M., Permanyer-Miralda, G., Ferreira-González, I., Busse, J. W., Pacheco-Huergo, V., Bryant, D., Alonso, J., Akl, E. A., Domingo-Salvany, A., Mills, E., Wu, P., Schünemann, H. J., Jaeschke, R., & Guyatt, G. H. (2005). Validity of composite end points in clinical trials. British medical journal, 330(7491), 594-596.